Navigation Links
Hypoxia Induces Stem Cell Gene Expression, Protein Production and Cell Surface Markers
Date:5/3/2010

Histogen, Inc., a regenerative medicine company developing solutions based on the products of newborn cells grown under embryonic conditions, will present new findings today at the International Conference on Stem Cell Engineering (ICSCE). Analysis of the cells grown under Histogen's proprietary conditions of hypoxia and low gravity show the expression of specific markers associated with embryonic stem cells.

San Diego, CA (PRWEB) May 3, 2010 -- Histogen, Inc., a regenerative medicine company developing solutions based on the products of newborn cells grown under embryonic conditions, will present new findings today at the International Conference on Stem Cell Engineering (ICSCE). Analysis of the cells grown under Histogen's proprietary conditions of hypoxia and low gravity show the expression of specific markers associated with embryonic stem cells.

Different cell types can be identified by unique profiles based on the genes they express, the proteins they produce, and markers that they have on their cell surface. Histogen has discovered that, under growth conditions of 2-5% oxygen (hypoxia) and low gravity, safe and non-controversial newborn skin cells (fibroblasts) acquire the profile of pluripotent stem cells.

"Over 5,000 genes are differentially expressed by these cells, as compared to fibroblasts grown under traditional conditions," said Dr. Gail K. Naughton, CEO and Chairman of the Board at Histogen. "What we are seeing is a shift in the profile of these cells to one that is more embryonic-like, more similar to stem cells than fibroblasts."

DNA microarray analysis revealed that, under hypoxic culture conditions, fibroblasts upregulate the expression of key embryonic stem cell markers including Oct4, Nanog, and Sox2. These specific genes are known to be critical in the generation of induced pluripotent stem cells. A number of other stem cell-associated markers, such as Brachyury, Gata4, CCR4, LIN28 and Nodal FGF5 were also expressed at higher levels in the hypoxic cultures as compared to fibroblasts grown under normal oxygen levels.

These studies suggest hypoxic culture of somatic cells in large-scale bioreactor systems is a potentially feasible and efficient method for obtaining and producing adequate amounts of pluripotent stem cells and associated factors for clinical regenerative medicine applications.

"Reprogramming adult, differentiated somatic cell types through chemical manipulation or genetic transfection to transform the cells into a dedifferentiated, pluripotent stem cell phenotype has been the focus of many recent studies," said Dr. Jonathan Mansbridge, Chief Scientific Officer at Histogen. "Although these experiments have demonstrated the ability to induce cells back to a pluripotent state, the methods used have raised considerable issues regarding mutagenicity and clinical safety. We now have preliminary evidence that, by altering the oxygen levels under which neonatal fibroblasts are cultured, there is potential for a viable pluripotent stem cell source that would be free of these issues."

Human extracellular matrix (hECM) compositions produced under the hypoxia/microgravity conditions discussed here are covered by pending US patent #2010/0047305. "Induction of Stem Cell Marker Expression in Human Dermal Fibroblasts in Hypoxic Culture Conditions" will be presented by Dr. Mansbridge at the ICSCE event, taking place May 2-5, 2010 in Boston, Mass.

About Histogen
Histogen, launched in 2007, seeks to redefine regenerative medicine by developing a series of high value products that do not contain embryonic stem cells or animal components. Through Histogen's proprietary bioreactors that mimic the embryonic environment, newborn cells are encouraged to naturally produce the vital proteins and growth factors from which the Company has developed its rich product portfolio. Histogen has two product families - a proprietary liquid complex of embryonic-like proteins and growth factors, and a human Extracellular Matrix (ECM) material, ExCeltrix. For more information, please visit http://www.histogen.com.

# # #

Read the full story at http://www.prweb.com/releases/2010/05/prweb3953054.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved

Related biology technology :

1. Therapeutic Proteins Inc. Completes First Independent, Dedicated Biosimilars Manufacturing Facility in U.S.
2. The Protein Structure Initiative announces free OpenHelix tutorial and training materials for the Structural Genomics Knowledgebase (SGKB)
3. RIKEN Plant Science Center Research Reveals the Proteins That Help Plants Keep Time
4. Bone Biologics Announces a Major US Patent Issuance For Its Recombinant Protein Process For the Formation of Cartilage
5. Atherotechs Advanced Lipid Profile Featured in Lipoprotein and Epidemiology Research at ACC 2010
6. Kinexus Announces the Launch of a New Protein Kinase Microarray
7. U of A led team makes breakthrough demonstration of pH-regulating protein
8. Cell Biosciences Acquires Protein Forest
9. Vibrations key to efficiency of green fluorescent protein
10. Promega HaloTag Protein Purification System Makes it Easier to Purify Difficult-to-Express Proteins
11. AvidBiotics Corp. Granted Key U.S. and European Patents on Unique Protein Modification Platform
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... WI (PRWEB) , ... June 23, 2016 , ... ... supplements, is pleased to announce the launch of their brand, UP4™ Probiotics, into ... for over 35 years, is proud to add Target to its list of ...
(Date:6/23/2016)... -- Houston Methodist Willowbrook Hospital has signed a ... serve as their official health care provider. As ... provide sponsorship support, athletic training services, and most ... athletes and families. "We are excited ... to bring Houston Methodist quality services and programs ...
(Date:6/23/2016)... SAN FRANCISCO , June 23, 2016   ... it has secured $1 million in debt financing from ... to ramp up automation and to advance its drug ... for its new facility. "SVB has been ... goes beyond the services a traditional bank would provide," ...
(Date:6/23/2016)... Ky. , June 23, 2016 ... two Phase 1 clinical trials of its complement ... placebo-controlled, single and multiple ascending dose studies designed ... pharmacodynamics (PD) of subcutaneous injection in healthy adult ... subcutaneously (SC) either as a single dose (ranging ...
Breaking Biology Technology:
(Date:6/20/2016)... , June 20, 2016 Securus Technologies, ... technology solutions for public safety, investigation, corrections and ... prisons involved, it has secured the final acceptance ... facilities for Managed Access Systems (MAS) installed. Furthermore, ... facilities to be installed by October, 2016. MAS ...
(Date:6/15/2016)... ALBANY, New York , June 15, 2016 ... published a new market report titled "Gesture Recognition Market ... Trends and Forecast, 2016 - 2024". According to the ... at USD 11.60 billion in 2015 and is ... and reach USD 48.56 billion by 2024.  ...
(Date:6/9/2016)... -- Paris Police Prefecture ... to ensure the safety of people and operations in several ... tournament Teleste, an international technology group specialised in ... that its video security solution will be utilised by ... safety across the country. The system roll-out is scheduled for ...
Breaking Biology News(10 mins):